Elevar Therapeutics
Lissa Nazal is an experienced clinical and research professional with a strong background in pharmaceuticals and therapeutics. Currently serving as the Director at Elevar Therapeutics since April 2022, Lissa previously held roles as Director at Rain Therapeutics and Associate Director at Revance Therapeutics, Inc. Other significant positions include Clinical Program Manager in Hematology at Astex Pharmaceuticals, Global Lead Study Manager in Oncology at Astellas Pharma, and Global Clinical Trial Manager in Neuroscience at Takeda. Lissa's earlier experience includes various roles in clinical research, including Senior Clinical Research Associate at PharmaNet and Clinical Research Associate II at Kendle International, as well as a Research Assistant/Study Coordinator at Children's Memorial Hospital.
This person is not in any teams
This person is not in any offices
Elevar Therapeutics
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.